MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

SurModics Company Profile (NASDAQ:SRDX)

Consensus Ratings for SurModics (NASDAQ:SRDX) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $30.00 (27.39% upside)

Analysts' Ratings History for SurModics (NASDAQ:SRDX)
Show:
DateFirmActionRatingPrice TargetActions
5/3/2016Barrington ResearchBoost Price TargetOutperform$27.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/27/2015Dougherty & CoInitiated CoverageBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/26/2014SidotiUpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for SurModics (NASDAQ:SRDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/2/2016Q2$0.09$0.20$16.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/28/2016Q116$0.17$0.38$14.58 million$16.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q415$0.19$0.30$15.30 million$17.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q315$0.21$0.26$14.86 million$15.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q2$0.20$0.19$14.09 million$14.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/29/2015Q414$0.21$0.25$14.30 million$14.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314$0.25$0.26$14.90 million$15.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214$0.23$0.27$14.84 million$14.62 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114$0.20$0.22$14.40 million$13.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/30/2014Q413$0.21$0.21$14.15 million$13.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313$0.22$0.26$14.32 million$14.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013Q3 2013$0.21$0.22$15.03 million$14.29 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q2 2013$0.21$0.20$13.92 million$13.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/30/2013Q1 2013$0.18$0.29$13.63 million$13.85 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q412$0.17$0.17$13.83 million$13.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2012$0.14$0.17ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012$0.15$0.14ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011$0.05$0.06ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2011$0.04$0.13ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/27/2011$0.08ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/26/2011$0.05ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for SurModics (NASDAQ:SRDX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.06$0.21$0.13
Q2 20163$0.09$0.17$0.12
Q3 20162$0.12$0.19$0.16
Q4 20161$0.10$0.10$0.10
(Data provided by Zacks Investment Research)
Dividend History for SurModics (NASDAQ:SRDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for SurModics (NASDAQ:SRDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/14/2016Bryan K PhillipsSVPSell1,816$23.44$42,567.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2016Joseph J StichVPSell1,000$23.33$23,330.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2016Susan E KnightDirectorSell1,001$22.71$22,732.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Timothy J ArensVPSell10,291$18.43$189,663.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015Joseph J StichVPSell1,000$21.18$21,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2015Joseph J StichVPSell1,000$23.57$23,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Joseph J StichVPSell1,000$23.84$23,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Bryan K PhillipsSVPSell7,293$25.25$184,148.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014Charles W OlsonVPSell5,083$21.98$111,724.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Charles W OlsonVPSell3,365$21.66$72,885.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Timothy J ArensVPSell10,330$21.02$217,136.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Susan KnightDirectorBuy1,500$20.36$30,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2013Bryan PhillipsSVPSell16,236$22.95$372,616.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Mark A LehmanInsiderSell1,693$26.55$44,949.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/10/2012Value Lp StarboardMajor ShareholderSell257,560$17.74$4,569,114.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for SurModics (NASDAQ:SRDX)
DateHeadline
06/29/16 07:03 AMInvest in These 5 Efficient Stocks for Healthy Returns -
06/03/16 07:59 AMMyriad Genetics Buys Sividon Diagnostics, Gains EndoPredict -
06/01/16 09:30 AMGNC Holdings Q1 Results Weak, Overseas Prospects Bright - and SurModics, Inc. (SRDX - Analyst Report) . While Baxter sports a Zacks Rank #1 (Strong Buy), Boston Scientific and SurModics carry a Zacks Rank #2 (Buy).
06/01/16 07:05 AMSurModics to Present at Jefferies Healthcare Conference - [Business Wire] - SurModics, Inc. , a leading provider of medical device and in vitro diagnostic technologies, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies Healthcare Conference in New York City on Tuesday, June 7, 2016, at 4 p.m.
05/25/16 07:05 AMSURMODICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement -
02/22/16 04:00 PMSURMODICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur -
02/16/16 07:05 AMSurModics to Host Virtual Shareholder Meeting on February 17 - [Business Wire] - SurModics, Inc. , a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Wednesday, February 17, at 4:00 p.m.
02/05/16 03:17 PMSURMODICS INC Files SEC form 10-Q, Quarterly Report -
02/03/16 03:15 PMSURMODICS INC Files SEC form 8-K/A, Financial Statements and Exhibits -
02/02/16 09:34 AMSurModics, Inc. Earnings Analysis: Q1, 2016 By the Numbers -
01/29/16 10:40 AMSurModics' (SRDX) Q1 Earnings & Revenues Beat Estimates -
01/28/16 01:15 PMSurModics, Inc Reports 44% Rise In Q1 Profit - SurModics, Inc (SRDX) reported earnings for its first quarter that climbed from last year. The company said its bottom line came in at $5.06 million, or $0.38 per share. This was up from $3.51 million, or $0.26 per share, in last year's first quarter.
01/28/16 07:30 AMSurModics Inc Earnings Call scheduled for 8:30 am ET today -
01/28/16 07:02 AMSurModics Reports First Quarter Fiscal 2016 Results - [at noodls] - GAAP Revenue of , up 16% GAAP EPS of , Non-GAAP EPS of Fiscal 2016 Guidance Reaffirmed --(BUSINESS WIRE)--Jan. 28, 2016-- (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies ...
01/28/16 06:55 AMSurModics posts 1Q profit -
01/28/16 06:51 AMSURMODICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
01/28/16 06:07 AMQ1 2016 SurModics Inc Earnings Release - Before Market Open -
01/21/16 07:15 AMSurModics to Webcast First Quarter 2016 Earnings Conference Call on January 28 - [at noodls] - Webcast is Live at --(BUSINESS WIRE)--Jan. 21, 2016-- (Nasdaq:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today that it will host ...
01/13/16 06:06 PMSurModics buys design and development firm NorMedix for $14M -
01/13/16 03:56 PMSURMODICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Dispositio -
01/12/16 02:22 PMSurModics Buys NorMedix for $14M, Adjusts 2016 Outlook -
01/12/16 11:30 AMSurModics increases exec pay; CEO Gary Maharaj got $1.48M in 2015 -
01/11/16 12:27 PMSurModics sees top line as high as $64M this year, non-GAAP EPS up to $0.75 -
01/11/16 07:18 AMSurModics Acquires NorMedix, a Design and Development Company Focused on Minimally Invasive Catheter Technologies - [at noodls] - Furthers transformation strategy with vascular expertise and R&D capabilities Brings unique catheter-based technology and development capabilities Raising revenue guidance to adjusted range of GAAP EPS ...
01/11/16 05:02 AMSURMODICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
01/08/16 06:55 AMSurModics Provides Updated 2016 Guidance - [at noodls] - GAAP Revenue Anticipated to Range from Expects GAAP Earnings Per Share of per share Expects Non-GAAP EPS of per share --(BUSINESS WIRE)--Jan. 8, 2016-- (Nasdaq:SRDX), a leading provider of medical device ...
01/07/16 07:22 AMSurModics to Webcast Updated Fiscal 2016 Financial Guidance Conference Call on January 8 - [at noodls] - Webcast is Live at --(BUSINESS WIRE)--Jan. 7, 2016-- (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today that it will host ...
12/23/15 05:03 AMSURMODICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws -
12/22/15 10:41 AMSurModics, Inc. Earnings Analysis: Q4, 2015 By the Numbers -
12/22/15 07:20 AMSurModics Announces Device Veteran Shawn McCormick Joins Board of Directors - [at noodls] - --(BUSINESS WIRE)--Dec. 22, 2015-- (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced the addition of a new independent board member, , a highly ...
12/10/15 12:04 PMSURMODICS INC Financials -
About SurModics

SurModics logoSurModics, Inc. is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company is focused on to transform its medical device business from being a provider of coating technologies to offering whole product solutions to medical device customers. The Company's Medical Device segment consists of surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company's In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. Its products include BioFX Liquid Nova-Stop Solution, StabilZyme Protein-Free AP Stabilizer, StabilZyme Protein-Free Stabilizer and StabilBlot Blocker Family.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Diagnostic Substances
  • Sub-Industry: Health Care Equipment
  • Exchange: NASDAQ
  • Symbol: SRDX
  • CUSIP: 86887310
Key Metrics:
  • Previous Close: $23.55
  • 50 Day Moving Average: $22.85
  • 200 Day Moving Average: $20.36
  • P/E Ratio: 36.03
  • P/E Growth: 2.06
  • Market Cap: $304.79M
  • Current Quarter EPS Consensus Estimate: $0.78 EPS
Additional Links:
SurModics (NASDAQ:SRDX) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha